Our understanding of the pathogenesis of diseases has advanced enormously in recent
decades. As a consequence, drug discovery has gradually shifted from an entirely …

No drug has been approved to prevent neuronal cell loss in patients suffering from
Parkinson's disease (PD) or Alzheimer's disease (AD); despite increased comprehension of …

We have previously synthesized a series of hybrid compounds by linking ferulic acid to
tacrine as multifunctional agents based on the hypotheses that Alzheimer's disease (AD) …

The therapeutic arsenal for the treatment of Alzheimer s disease (AD) remains confined to a
group of four inhibitors of AChE and one NMDA receptor antagonist, which are used to …

Neurodegenerative diseases (NDs) represent one of the most important public health
problems and concerns, as they are a growing cause of mortality and morbidity worldwide …

Iron accumulation or iron overload in brain is commonly associated with neurodegenerative
disorders such as Parkinson's and Alzheimer's diseases, and also plays a role in cellular …

The concept of chelation therapy as a valuable therapeutic approach in neurological
disorders led us to develop multi-target, non-toxic, lipophilic, brain-permeable compounds …

Alzheimer's disease (AD) is a multifactorial syndrome with several target proteins
contributing to its etiology. To confront AD, an innovative strategy is to design single …

Considering the multi-etiological character of Alzheimer's disease (AD), the current
pharmacological approaches using drugs oriented towards a single molecular target …

Tacrine–melatonin hybrids are potential multifunctional drugs for Alzheimer's disease that
may simultaneously palliate intellectual deficits and protect the brain against both β‐amyloid …